摘要
产品跳跃有改换形式、添加或移除某些化合物、将单独出售的两种或以上药物以组合形式重新包装等形式,常常被视为原研药企阻击竞争对手仿制药企的一种战略,从而受到反垄断的审查和规制。然而,排除那些存在制造隐患、恶意诋毁或创新骗局外,更多的产品跳跃是一种创新活动,对其严苛监管既有悖市场竞争规则,也很难权衡利弊得失,从长远角度来看还会在很大程度上抑制整个行业的发展并最终传导到消费者,降低全社会福祉。
Product hopping in the form of change, the addition or removal of certain compounds, the sale of two or more drugs sold in the form of a combination of repackaging and other forms, were often seen as strategies for the brand-name pharmaceutical manufacturer to ban the generic pharmaceutical company entering the market, thus it is under antitrust scrutiny and regulation. However, excluding the manufacturing defects, the ma/icious slander or innovation scheme, more products hopping is a kind of innovative activities, and strict management to it will not only be contrary to the rules of market competition, but also be difficult to weigh the pros and cons from a long- term perspective, which will greatly inhibit the development of the industry, ultimately influence the benefits of consumers, and reduce the total social welfare.
作者
王艳
胡允银
WANG Yan HU Yunyin(Taizhou Radio and Television University, Taizhou 318000, China School of Trade and Economic Management, Taizhou University, Taizhou 318000, China Zhejiang Tiansong Law Firm, Taizhou 318000, China)
出处
《科技管理研究》
CSSCI
北大核心
2017年第11期23-27,共5页
Science and Technology Management Research
基金
国家社会科学基金项目"‘战略-形象’协同视角下国家知识产权形象建设研究(13BGL003)
关键词
品牌制药企业
仿制药企业
产品跳跃
反竞争
brand-name pharmaceutical manufacturer
generic pharmaceutical company
product hopping
anti- competitive
